Thank you for participating in our presentation.

Q1I am a(n)...
 MD/DO NP PA Other
Q3How many years have you been in practice?
 1-5 6-10 11-15 16-20 Over 20
Q4Number of patients do you see per month with...?
 1-10 11-20 21-30 31-40 41-50 Over 50
Q5Please describe your practice setting:
 Solo Practice Group Practice Hospital Setting Clinic Other
Q7Please rate the following:
 Unsatisfactory Needs Improvement Average Above Average Excellent
 Degree to which educational expectations were met    
 Material was relevant to my practice    
 Effective Faculty Presenter    
 Overall Program    
Q8Please rate your ability to achieve the Learning Objectives below:
 Not at all Somewhat Mostly Completely
 Identify the risks of kidney disease and their consequences in patients with type 2 diabetes (T2DM)   
 Appropriately screen for the presence of chronic kidney disease (CKD) in patients with T2DM    
 Initiate evidence-based therapy to slow the progression of kidney disease inpatients with T2DM and CKD   
 Become familiar with the mineralocorticoid receptor antagonist (MRA) and its role in treatment of patients with diabetic kidney disease (DKD).   
Q9Will you change your practice behaviors as a result of this presentation?
 No Unlikely No Opinion Probably Absolutely
Q10What will you change? Select as many of the following as you deem appropriate.
Q11Which medications are you now more likely to prescribe? You may select one, both, or neither.
Q14What barriers do you see to change?
 Cost Insurance Coverage Formulry Time with patient Patient adherence Other
Q16Did the content contribute valuable information that will assist in improving patient outcomes?
 Strongly Disagree Disagree Neutral Agree Strongly Agree
Q17What was your level of expertise on this topic?
 None Little Some Considerable Extensive
 Before this presentation    
 AFTER this presentation    
Q18Do you believe the activity was fair and balanced, free from commercial influences?
 Yes No
Q19Did the program increase your competence?
 Yes No
Q20According to the 2022 ADA Standards of Medical Care in Diabetes, for which group of patients with diabetes and CKD is finerenone recommended?
Q21Which of the following is a benefit of non-steroidal mineralocorticoid receptor antagonists (MRAs) but not of steroidal MRAs?
Q22How confident do you feel in your answer to the previous question?
 Not at all confident Somewhat confident Confident Very confident


dividing line